Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
Day's Change
0.0389 (37.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Kirkland's stock dips premarket as promise of better times in 2023 offsets quarterly loss and sales miss

8:45 am ET December 2, 2022 (MarketWatch)

Kirkland's Inc. stock pared early gains to trade down 1.6% premarket Friday, after the specialty retailer of home decor and furnishings . Nashville, Tenn.-based Kirkland's swung to a loss of $7.3 million, or 58 cents a share, after income of $7.2 million, or 51 cents a share, in the year-earlier period. The company's adjusted per-share loss came to 38 cents, wider than the 32 cent FactSet consensus. Sales fell to $131.0 million from $143.6 million a year ago, below the FactSet consensus of $134.0 million. Same-store sales fell 7%, while FactSet expected a decline of 3%. Chief Executive Steve Woodward said the performance was in line with the company's own expectations. "We experienced an encouraging rebound in sales through August and our Labor Day promotional event, but we believe persistent macro-economic pressures hampered our customers during the Harvest selling season, resulting in softer sales for the back half of the quarter," he said, a trend that has been reported by other retailers, including Target Corp. and Macy's Inc. . However, sales have improved in the fourth quarter as holiday merchandise has filled shelves, said Woodward. "We've made good initial progress reducing inventories, and we have already made a substantial reduction in our borrowings," he said. "Additionally, supply chain disruptions have eased, and inbound freight rates have declined. While we won't see a significant benefit from these factors until we've worked through our current inventory, we expect it to show in our merchandise margin in fiscal 2023 and beyond." The company is expecting 2023 to be a year of stabilization, he said. Shares have fallen 74% in the year to date, while the S&P 500 has fallen 14%.

-Ciara Linnane


(END) Dow Jones Newswires

December 02, 2022 08:45 ET (13:45 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.